Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies.

Context.--Rapid advancements in the understanding and manipulation of tumor-immune interactions have led to the approval of immune therapies for patients with non--small cell lung cancer. Certain immune checkpoint inhibitor therapies require the use of companion diagnostics, but methodologic variabi...

Descripción completa

Detalles Bibliográficos

Publicado en:	Archives of Pathology & Laboratory Medicine Vol. 148; no. 7; pp. 757 - 775
Autores principales:	Sholl, Lynette M., Awad, Mark, Roy, Upal Basu, Beasley, Mary Beth, Cartun, Richard Walter, Hwang, David M., Kalemkerian, Gregory, Lopez-Rios, Fernando, Mino-Kenudson, Mari, Paintal, Ajit, Reid, Kearin, Ritterhouse, Lauren, Souter, Lesley A., Swanson, Paul E., Ventura, Christina B., Furtado, Larissa V.
Formato:	practice guidelines research systematic review tables/charts Journal Article
Publicado:	College of American Pathologists Jul2024
Acceso en línea:	Ver este registro en EBSCOhost